These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 33942901)

  • 1. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
    Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
    Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with a Tmprss6 RNAi-therapeutic and the oral iron chelator deferiprone additively diminishes secondary iron overload in a mouse model of β-thalassemia intermedia.
    Schmidt PJ; Racie T; Westerman M; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2015 Apr; 90(4):310-3. PubMed ID: 25557851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
    Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
    Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi-mediated reduction of hepatic Tmprss6 diminishes anemia and secondary iron overload in a splenectomized mouse model of β-thalassemia intermedia.
    Schmidt PJ; Liu K; Visner G; Fitzgerald K; Fishman S; Racie T; Hettinger JL; Butler JS; Fleming MD
    Am J Hematol; 2018 Jun; 93(6):745-750. PubMed ID: 29498084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia.
    Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C
    Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of Tmprss6- ASO and the iron chelator deferiprone improves erythropoiesis and reduces iron overload in a mouse model of beta-thalassemia intermedia.
    Casu C; Aghajan M; Oikonomidou PR; Guo S; Monia BP; Rivella S
    Haematologica; 2016 Jan; 101(1):e8-e11. PubMed ID: 26405152
    [No Abstract]   [Full Text] [Related]  

  • 7. Correcting β-thalassemia by combined therapies that restrict iron and modulate erythropoietin activity.
    Casu C; Pettinato M; Liu A; Aghajan M; Lo Presti V; Lidonnici MR; Munoz KA; O'Hara E; Olivari V; Di Modica SM; Booten S; Guo S; Neil G; Miari R; Shapir N; Zafir-Lavie I; Domev H; Ferrari G; Sitara D; Nai A; Rivella S
    Blood; 2020 Oct; 136(17):1968-1979. PubMed ID: 32556142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulated erythropoiesis with secondary iron loading leads to a decrease in hepcidin despite an increase in bone morphogenetic protein 6 expression.
    Frazer DM; Wilkins SJ; Darshan D; Badrick AC; McLaren GD; Anderson GJ
    Br J Haematol; 2012 Jun; 157(5):615-26. PubMed ID: 22449175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global loss of Tfr2 with concomitant induced iron deficiency greatly ameliorates the phenotype of a murine thalassemia intermedia model.
    Schmidt PJ; Fitzgerald K; Butler JS; Fleming MD
    Am J Hematol; 2021 Feb; 96(2):251-257. PubMed ID: 33180328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing TMPRSS6 ameliorates hemochromatosis and β-thalassemia in mice.
    Guo S; Casu C; Gardenghi S; Booten S; Aghajan M; Peralta R; Watt A; Freier S; Monia BP; Rivella S
    J Clin Invest; 2013 Apr; 123(4):1531-41. PubMed ID: 23524968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia.
    Liu J; Liu W; Liu Y; Miao Y; Guo Y; Song H; Wang F; Zhou H; Ganz T; Yan B; Liu S
    Haematologica; 2019 Sep; 104(9):1768-1781. PubMed ID: 30792208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.
    Kautz L; Jung G; Du X; Gabayan V; Chapman J; Nasoff M; Nemeth E; Ganz T
    Blood; 2015 Oct; 126(17):2031-7. PubMed ID: 26276665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron and hepcidin: a story of recycling and balance.
    Camaschella C
    Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Oral Ferroportin Inhibitor VIT-2763 Improves Erythropoiesis without Interfering with Iron Chelation Therapy in a Mouse Model of β-Thalassemia.
    Nyffenegger N; Flace A; Doucerain C; Dürrenberger F; Manolova V
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice.
    Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S
    J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oral iron chelator deferiprone protects against systemic iron overload-induced retinal degeneration in hepcidin knockout mice.
    Song D; Zhao L; Li Y; Hadziahmetovic M; Song Y; Connelly J; Spino M; Dunaief JL
    Invest Ophthalmol Vis Sci; 2014 Jun; 55(7):4525-32. PubMed ID: 24970260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.
    Schmidt PJ; Fleming MD
    Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SLN124, a GalNAc conjugated 19-mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers.
    Porter JB; Scrimgeour A; Martinez A; James L; Aleku M; Wilson R; Muckenthaler M; Boyce M; Wilkes D; Schaeper U; Campion GV
    Am J Hematol; 2023 Sep; 98(9):1425-1435. PubMed ID: 37497888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice.
    Wake M; Palin A; Belot A; Berger M; Lorgouilloux M; Bichon M; Papworth J; Bayliss L; Grimshaw B; Rynkiewicz N; Paterson J; Poindron A; Spearing E; Carter E; Hudson R; Campbell M; Petzer V; Besson-Fournier C; Latour C; Largounez A; Gourbeyre O; Fay A; Coppin H; Roth MP; Theurl I; Germaschewski V; Meynard D
    Blood Adv; 2024 Apr; 8(8):1898-1907. PubMed ID: 38241484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.